Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib and Itacitinib in B-Cell Malignancies (CITADEL-101)
NCT02018861Phase 2Completed
- Sponsor
- Incyte
- Start
- Sep 2016
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of parsaclisib in B cell malignancies, non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), sponsored by Incyte. Started Sep 2016; status: completed.
02
Drugs
parsaclisib
03
Conditions
B cell malignanciesnon-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)chronic lymphocytic leukemia (CLL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02018861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02018861.